TheGame46
Member
Hexatropin Profile
Summary: The active ingredient in Hexatropin is GH-releasing hexapeptide (GHRP-6). This peptide has been clinically verified to increase growth hormone levels, increase appetite, raise IGF-1 levels, help sleep cycles and more. Hexatropin uses the newest peptide delivery technology that does not go through the digestive system but passes directly into you blood stream through mechanism regulated by you own cheek cells. (see below for details)
Cell-Mediated™ GHRP-6 and Hexarelin
(for oral use)
100% Bioavailability, Orally Active, Sustained 24-48 hours
Each kit contains:
2.0mg Cell-Mediated™ GHRP-6
2.0mg Cell-Mediated™ Hexarelin
20 individually sealed oral syringes for ease in daily dosing,
no measurements, no hassles.
Each oral syringe contains:
100mcg Cell-Mediated™ GHRP-6
100mcg Cell-Mediated™ Hexarelin
sustained 24-48 hrs
0.5 cc's (0.661g) HexaTropin-6™
SUGGESTED RETAIL: $140.00
GH-releasing hexapeptide (GHRP-6) is a secratogue that stimulates the release of growth hormone (GH) by acting at both hypothalamic and pituitary sites which has been clinically documented in a wide variety of species in vivo and in vitro. GHRP-6 duplicates the way the growth hormone works in the body. In studies it not only has shown to enhance growth hormone levels, but also increased the pulsatile secretory bursts of GH. Another remarkable trait of GHRP-6 is its increase in normal pulsatile physiological secretion by its hypothalamic action. Initial studies with GHRP-6 suggested that this compound acted primarily on the pituitary gland and was absolutely specific for GH release. More recent studies have qualified both of these assumptions. This peptide has been clinically verified to increase GH levels, increase appetite, raise IGF-1 levels, help sleep cycles and more.
A recent study has verified that a 24 hr constant iv infusion of GHRP-6 neurophysiologically (via the central nervous system) activated the GH-IGF-1 axis by activating GH secretory burst mass and amplitude by 7 -to 10-fold and increasing the basal (nonpulsitile) GH secretion by 4.5 fold.
Why did we add Hexarelin?
Like GHRP-6, hexarelin is a six-amino acid peptide that significantly releases growth hormone. Studies have shown that hexarelin is actually more effective and longer lasting than growth hormone releasing hormone (GHRH). It is also known that GHRP-6 has a synergistic effect with GHRH, causing a far greater release than either of these substances alone. By combining GHRP-6 with Hexarelin, we have created a more potent GH releasing peptide combination than ever heard of. The potential clinical usefulness of these GH releasing hexapeptides is also reinforced by observations that long-term administration produces elevations in circulating IGF-1 concentrations. Long term treatment with GHRP-6 similarly has been shown to elevate serum IGF-1 as well as IGF-binding protein-3 concentrations, alter body composition and promote linear growth.
Hexarelin and other GH secratogues show similar potential usefulness by clinical observations that long-term administration produces elevations in circulating IGF-1 concentrations. For example, significant increases in plasma IGF-1 concentrations were noted after 7 days of hexarelin infusion and have even been reported after 7 days of intranasal administration in children and in adults after 7 to 14 days of intranasal hexarelin administration. It is also of interest that long-term administration of hexarelin has been shown to significantly increase circulating GH concentrations as well. The potential clinical utility of these GH secratogues is due to the consistent clinical verification of these findings in individuals of many ages.
Summary: The active ingredient in Hexatropin is GH-releasing hexapeptide (GHRP-6). This peptide has been clinically verified to increase growth hormone levels, increase appetite, raise IGF-1 levels, help sleep cycles and more. Hexatropin uses the newest peptide delivery technology that does not go through the digestive system but passes directly into you blood stream through mechanism regulated by you own cheek cells. (see below for details)
Cell-Mediated™ GHRP-6 and Hexarelin
(for oral use)
100% Bioavailability, Orally Active, Sustained 24-48 hours
Each kit contains:
2.0mg Cell-Mediated™ GHRP-6
2.0mg Cell-Mediated™ Hexarelin
20 individually sealed oral syringes for ease in daily dosing,
no measurements, no hassles.
Each oral syringe contains:
100mcg Cell-Mediated™ GHRP-6
100mcg Cell-Mediated™ Hexarelin
sustained 24-48 hrs
0.5 cc's (0.661g) HexaTropin-6™
SUGGESTED RETAIL: $140.00
GH-releasing hexapeptide (GHRP-6) is a secratogue that stimulates the release of growth hormone (GH) by acting at both hypothalamic and pituitary sites which has been clinically documented in a wide variety of species in vivo and in vitro. GHRP-6 duplicates the way the growth hormone works in the body. In studies it not only has shown to enhance growth hormone levels, but also increased the pulsatile secretory bursts of GH. Another remarkable trait of GHRP-6 is its increase in normal pulsatile physiological secretion by its hypothalamic action. Initial studies with GHRP-6 suggested that this compound acted primarily on the pituitary gland and was absolutely specific for GH release. More recent studies have qualified both of these assumptions. This peptide has been clinically verified to increase GH levels, increase appetite, raise IGF-1 levels, help sleep cycles and more.
A recent study has verified that a 24 hr constant iv infusion of GHRP-6 neurophysiologically (via the central nervous system) activated the GH-IGF-1 axis by activating GH secretory burst mass and amplitude by 7 -to 10-fold and increasing the basal (nonpulsitile) GH secretion by 4.5 fold.
Why did we add Hexarelin?
Like GHRP-6, hexarelin is a six-amino acid peptide that significantly releases growth hormone. Studies have shown that hexarelin is actually more effective and longer lasting than growth hormone releasing hormone (GHRH). It is also known that GHRP-6 has a synergistic effect with GHRH, causing a far greater release than either of these substances alone. By combining GHRP-6 with Hexarelin, we have created a more potent GH releasing peptide combination than ever heard of. The potential clinical usefulness of these GH releasing hexapeptides is also reinforced by observations that long-term administration produces elevations in circulating IGF-1 concentrations. Long term treatment with GHRP-6 similarly has been shown to elevate serum IGF-1 as well as IGF-binding protein-3 concentrations, alter body composition and promote linear growth.
Hexarelin and other GH secratogues show similar potential usefulness by clinical observations that long-term administration produces elevations in circulating IGF-1 concentrations. For example, significant increases in plasma IGF-1 concentrations were noted after 7 days of hexarelin infusion and have even been reported after 7 days of intranasal administration in children and in adults after 7 to 14 days of intranasal hexarelin administration. It is also of interest that long-term administration of hexarelin has been shown to significantly increase circulating GH concentrations as well. The potential clinical utility of these GH secratogues is due to the consistent clinical verification of these findings in individuals of many ages.